Guggenheim Maintains Buy on Medpace Hldgs, Lowers Price Target to $432
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Sandy Draper maintains a Buy rating on Medpace Holdings (NASDAQ:MEDP) but lowers the price target from $464 to $432.

July 24, 2024 | 11:46 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Guggenheim analyst Sandy Draper maintains a Buy rating on Medpace Holdings but lowers the price target from $464 to $432.
The Buy rating suggests continued confidence in Medpace Holdings' performance, but the lowered price target indicates a more cautious outlook on its short-term valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100